More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/CHS-828 [200484-11-3]
Chemical Structure
Chemical Structure
Chemical Structure

CHS-828 [200484-11-3]

Research Use Only
AG-CR1-0064
AdipoGen Life Sciences
CAS Number200484-11-3
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight371.9
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    CHS-828 [200484-11-3]
  • Delivery Days Customer
    10
  • CAS Number
    200484-11-3
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C19H22ClN5O
  • Molecular Weight
    371.9
  • Scientific Description
    Antitumor compound [1, 2, 8]. Programmed cell death inducer [3-5]. Cytotoxic [6, 7, 14]. Antiproliferative [11]. p53 activator [9]. IkappaB kinase inhibitor [10]. NF-kappaB inhibitor [10, 12]. Nampt/visfatin inhibitor [13, 15, 16]. - Chemical. CAS: 200484-11-3. Formula: C19H22ClN5O. MW: 371.9. Antitumor compound. Programmed cell death inducer. Cytotoxic. Antiproliferative. p53 activator. IkappaB kinase inhibitor. NF-kappaB inhibitor. Nampt/visfatin inhibitor.
  • SMILES
    ClC1=CC=C(OCCCCCCN\C(NC2=CC=NC=C2)=N/C#N)C=C1
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo: P.J. Hjarnaa, et al.; Cancer Res. 59, 5751 (1999)
  • Novel cyanoguanidines with potent oral antitumour activity: C. Schou, et al.; Bioorg. Med. Chem. Lett. 24, 3095 (1997)
  • Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells: P. Martinsson, et al.; Eur. J. Cancer 37, 260 (2001)
  • Cyanoguanidine CHS 828 induces programmed cell death with apoptotic features in human breast cancer cells in vitro: C.M. Hansen, et al.; Anticancer Res. 20, 4211 (2000)
  • Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells: P. Martinsson, et al.; Eur. J. Pharmacol. 417, 181 (2001)
  • Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action: S.B. Hassan, et al.; J. Pharmacol. Exp. Ther. 299, 1140 (2001)
  • Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1: H. Lövborg, et al.; Cancer Res. 62, 4206 (2002)
  • A Phase I study of CHS 828 in patients with solid tumor malignancy: P. Hovstadius, et al.; Clin. Cancer Res. 8, 2843 (2002)
  • Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828: J. Wojciechowski, et al.; Drugs Exp. Clin. Res. 29, 53 (2003)
  • Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity: L.S. Olsen, et al.; Int. J. Cancer 111, 198 (2004)